Core Viewpoint - The article discusses the significant changes in the control of Sailong Pharmaceutical Group Co., Ltd. (*ST Sailong, 002898) following the signing of a share transfer agreement, alongside the company's poor financial performance leading to a delisting risk warning. Group 1: Share Transfer and Control Change - The controlling shareholders, Cai Nanguai and Tang Lin, signed a share transfer agreement to sell 14.16% of the company's shares to Hainan Yayi, amounting to a total transaction value of RMB 199,297,640.00 at a price of RMB 8 per share [1] - Following the transaction, Hainan Yayi will become the controlling shareholder, and the company will have no actual controller since Hainan Yayi currently has no actual controller [1] - The shareholding structure will change significantly, with Cai Nanguai's shareholding dropping from 51.15% to 38.36%, and Tang Lin's from 5.47% to 4.10% [1] Group 2: Financial Performance - Sailong Pharmaceutical reported a revenue of RMB 263.57 million in 2024, a decrease of 15.15% compared to 2023, and a net loss of RMB 33.15 million, a decline of 447.67% year-on-year [2][3] - The company has been issued a delisting risk warning due to its negative net profit and revenue falling below RMB 300 million [3][4] Group 3: Regulatory Actions - The company received a warning letter from the Guangdong Securities Regulatory Bureau due to discrepancies between its earnings forecast and actual performance, as well as failure to disclose potential delisting risks in a timely manner [4][5] - Key executives, including the chairman and financial director, were held responsible for the company's non-compliance with disclosure regulations [5] Group 4: New Shareholder Background - Hainan Yayi, the acquiring entity, was established on May 15, 2025, specifically for this transaction and currently has no actual business operations [6] - The partnership structure of Hainan Yayi indicates that it lacks an actual controller, with decision-making requiring unanimous agreement among partners [8]
濒临退市的A股公司,2亿卖了控股权,接盘方无实控人